Diaceutics PLC
LSE:DXRX
Diaceutics PLC
LSE:DXRX
Price:
114.5 GBX
4.09%
Market Closed
Updated:
May 18, 2024
Balance Sheet
Balance Sheet Decomposition
Diaceutics PLC
Diaceutics PLC
| Current Assets | 28m |
| Cash & Short-Term Investments | 17.9m |
| Receivables | 9.2m |
| Other Current Assets | 874k |
| Non-Current Assets | 18.2m |
| PP&E | 2m |
| Intangibles | 16.1m |
| Other Non-Current Assets | 96k |
| Current Liabilities | 3.5m |
| Accounts Payable | 287k |
| Accrued Liabilities | 1.7m |
| Other Current Liabilities | 1.5m |
| Non-Current Liabilities | 1.6m |
| Long-Term Debt | 1.1m |
| Other Non-Current Liabilities | 429k |
Balance Sheet
Diaceutics PLC
Diaceutics PLC
Currency: GBP
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
1
|
3
|
2
|
12
|
25
|
20
|
20
|
|
| Cash |
1
|
3
|
2
|
12
|
25
|
20
|
20
|
|
| Total Receivables |
2
|
2
|
4
|
6
|
8
|
10
|
10
|
|
| Accounts Receivables |
2
|
2
|
4
|
6
|
5
|
7
|
8
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
2
|
3
|
2
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
|
| Total Current Assets |
3
|
5
|
6
|
18
|
34
|
30
|
31
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
2
|
2
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
2
|
2
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Intangible Assets |
0
|
0
|
1
|
4
|
9
|
13
|
15
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
3
N/A
|
5
+60%
|
8
+42%
|
22
+186%
|
44
+95%
|
45
+3%
|
48
+7%
|
|
| Liabilities | ||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Accrued Liabilities |
1
|
1
|
1
|
1
|
2
|
2
|
2
|
|
| Short-Term Debt |
0
|
0
|
2
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Current Liabilities |
1
|
2
|
4
|
2
|
3
|
3
|
4
|
|
| Long-Term Debt |
1
|
2
|
1
|
0
|
0
|
1
|
1
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
2
N/A
|
4
+49%
|
5
+43%
|
2
-57%
|
3
+47%
|
4
+33%
|
6
+32%
|
|
| Equity | ||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1
|
2
|
2
|
3
|
3
|
4
|
5
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
17
|
37
|
37
|
37
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1
N/A
|
2
+86%
|
3
+40%
|
20
+666%
|
40
+100%
|
41
+1%
|
43
+5%
|
|
| Total Liabilities & Equity |
3
N/A
|
5
+60%
|
8
+42%
|
22
+186%
|
44
+95%
|
45
+3%
|
48
+7%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
70
|
70
|
70
|
70
|
84
|
84
|
84
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
